13D Filings
Tectonic Therapeutic, Inc.
TECX
Amendment
Ownership

0.00%

Total Shares

0

Issuer CIK

1681087

Event Date

Mar 3, 2025

Accepted

Apr 7, 2025, 04:20 PM

Reporting Persons (3)
Joint Filing

This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.

NameType% of ClassAggregateSole VotingShared Voting
Vida Ventures II, LLC
Other
0.00%000
Vida Ventures II-A, LLC
Other
0.00%000
VV Manager II, LLC
Other
0.00%000
Disclosure Items (6)

Security Title

Common Stock, $0.0001 par value per share

Issuer Name

Tectonic Therapeutic, Inc.

Issuer Address

490 Arsenal Way, Suite 210, Watertown, MA, 02472

Filing Persons

The information set forth in Item 2(a) of the Original Schedule 13D is incorporated herein by reference.

Business Address

The information set forth in Item 2(b) of the Original Schedule 13D is incorporated herein by reference.

Principal Occupation

The information set forth in Item 2(c) of the Original Schedule 13D is incorporated herein by reference.

Convictions

The information set forth in Item 2(e) of the Original Schedule 13D is incorporated herein by reference.

Citizenship

The information set forth in Item 2(f) of the Original Schedule 13D is incorporated herein by reference.

The information set forth in Item 3 of the Original Schedule 13D is incorporated herein by reference.

The information set forth in Item 4 of the Original Schedule 13D is incorporated herein by reference.

Percentage of Class

See Items 7-11 of the cover pages of this Amendment No. 2. The information reported on such cover pages is reported as of March 4, 2025.

Number of Shares

See Items 7-11 of the cover pages of this Amendment No. 2. The information reported on such cover pages is reported as of March 4, 2025.

Transactions

On February 14, 2025, Vida II effected a pro rata distribution of 934,949 shares of Common Stock to its members without additional consideration. On February 14, 2025, Vida II-A effected a pro rata distribution of 25,944 shares of Common Stock to its members without additional consideration. On February 18, 2025, Vida II sold 7,881 shares of Common Stock at a weighted average price per share of $33.2498 for aggregate proceeds of approximately $261,577.63.On February 18, 2025, Vida II-A sold 219 shares of Common Stock at a weighted average price per share of $33.2498 for aggregate proceeds of approximately $7,258.52. On February 28, 2025, Vida II sold 20,345 shares of Common Stock at a weighted average price per share of $25.6818 for aggregate proceeds of approximately $521,419.67. On February 28, 2025, Vida II-A sold 565 shares of Common Stock at a weighted average price per share of $25.6818 for aggregate proceeds of approximately $14,468.89. On March 3, 2025, Vida II sold 584 shares of Common Stock at a weighted average price per share of $24.9606 for aggregate proceeds of approximately $14,468.79. On March 3, 2025, Vida II-A sold 16 shares of Common Stock at a weighted average price per share of $24.9606 for aggregate proceeds of approximately $401.49. On March 4, 2025, Vida II sold 37,140 shares of Common Stock at a weighted average price per share of $23.0841 for aggregate proceeds of approximately $855,438.36. On March 4, 2025, Vida II-A sold 1,031 shares of Common Stock at a weighted average price per share of $23.0841 for aggregate proceeds of approximately $23,737.58.

Shareholders

The information set forth in Item 5(d) of the Original Schedule 13D is incorporated herein by reference.

Date of 5% Ownership

March 4, 2025

The information set forth in Item 6 of the Original Schedule 13D is incorporated herein by reference.